Early decline in heart function predicts heart damage from doxorubicin in lymphoma patients
Author Information
Author(s): Nousiainen T, Jantunen E, Vanninen E, Hartikainen J
Primary Institution: Kuopio University Hospital and University of Kuopio
Hypothesis
Can early decline in left ventricular ejection fraction after low cumulative doxorubicin dose predict later heart function impairment?
Conclusion
The study found that early impairment of heart function during doxorubicin therapy can be predicted at low cumulative doses.
Supporting Evidence
- Left ventricular ejection fraction decreased significantly after doxorubicin doses.
- 36% of patients experienced a decrease in ejection fraction to below 50%.
- Two patients developed clinical heart failure after treatment.
Takeaway
Doctors can tell if a cancer treatment might hurt the heart early on, even with a small amount of medicine.
Methodology
Thirty adult patients with non-Hodgkin's lymphoma were monitored for heart function using radionuclide ventriculography after receiving doxorubicin.
Potential Biases
Potential bias due to the exclusion of patients with prior heart conditions.
Limitations
The small sample size may limit the generalizability of the findings.
Participant Demographics
28 patients, mean age 53 years, 17 men and 11 women, 21% aged 65 or older.
Statistical Information
P-Value
p=0.001
Confidence Interval
95% CI=0.713–1.004
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website